PT  - JOURNAL ARTICLE
AU  - Solanki, Neha
AU  - Beck, Brittany
AU  - Labadia, Monica
AU  - Smith, Kevin
AU  - Peterson, Laura
AU  - King, Stephanie
AU  - Micklewright, Sarah
AU  - Pennington, Emily
AU  - Farooq, Sobia
AU  - Zhang, Peng
AU  - Aronica, Mark
AU  - Zein, Joe
AU  - Khatri, Sumita
AU  - Comhair, Suzy
AU  - Erzurum, Serpil
TI  - The Role of ACT Score in Mepolizumab Discontinuation
AID  - 10.1101/2023.09.28.23296286
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.28.23296286
4099  - http://medrxiv.org/content/early/2023/11/02/2023.09.28.23296286.short
4100  - http://medrxiv.org/content/early/2023/11/02/2023.09.28.23296286.full
AB  - Background Mepolizumab is a therapy for severe asthma. However, studies on mepolizumab with external validity and diverse population from the US are lacking. There is little knowledge of the characteristics of people that discontinue mepolizumab in clinical care.Objective To investigate the real-world efficacy and time to clinical discontinuation of mepolizumab, we evaluated individuals with asthma started on mepolizumab at the Cleveland Clinic. We hypothesized that there are characteristics that distinguish which patients would remain on mepolizumab and which patients would discontinue the medication.Methods Between 2016 and 2022, patients who started on mepolizumab consented to be assessed over 18 months. At baseline, a questionnaire including demographic and medical history was collected. Laboratory findings such as ACT score, FENO (Fractional Excretion of Nitric Oxide), and spirometry were recorded. At the conclusion of the observation period, the participants were divided into two categories: Group A and Group B.Results Group B [N=28] discontinued mepolizumab (P < 0.05) at an average of 5.8 months (SD 4.2 months). Group A [N=129] stayed on the therapy for at least 1 year. A participant with an ACT score less than 13 has an odds ratio of 6.64 (95% CI, 2.1 – 26.0) of discontinuing mepolizumab therapy. For a male, the odds of discontinuing mepolizumab therapy is 3.39 (95% CI, 1.1 – 11.2).Conclusion In this real-world study, we find that high eosinophil count may not be adequate in screening which individuals will benefit from mepolizumab. Up to 17% of patients fail therapy within 6 months, with male sex and low ACT score increasing risk of mepolizumab discontinuation at Cleveland Clinic.Competing Interest StatementAll authors declare that they have received no support from any organization for the submitted work; MA does consultancy for Sanofi, EP did consultancy for AstraZeneca over two years ago; no other relationships or activities that could appear to have influenced the submitted work. Funding StatementThe study was supported by the National Heart, Lung, and Blood Institute (HL103453 and HL081064). NS was supported by the Cleveland Clinic Catalyst Grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB #8351 of Cleveland Clinic gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.ACTasthma control testAUCarea under curveBMIbody mass indexCADcoronary artery diseaseCBCcomplete blood countCHFcongestive heart failureDBPdiastolic blood pressureFDAFederal Drug AdministrationFENOfractional excretion of nitric oxideFEV1forced expiratory volume in one secondGERDgastroesophageal reflux diseaseGINAGlobal Initiative for AsthmaGSKGlaxoSmithKlineICSinhaled corticosteroidsIQRinterquartile rangeIRBInstitutional Review BoardLABALong-acting beta agonistμLmicrolitersROCreceiver operating curveSBPsystolic blood pressureWBCwhite blood cell